Cash and cash equivalents (USD, thousands)

Short-term investments (USD, thousands)

Accounts receivable (USD, thousands)

Inventory (USD, thousands)

Prepaid expenses and other current assets (USD, thousands)

Total current assets (USD, thousands)

Property and equipment, net (USD, thousands)

Operating lease right-of-use asset (USD, thousands)

Restricted cash (USD, thousands)

Deferred offering costs (USD, thousands)

Other assets (USD, thousands)

Total assets (USD, thousands)

Accounts payable (USD, thousands)

Accrued liabilities (USD, thousands)

Operating lease liability (USD, thousands)

Deferred revenue (USD, thousands)

Total current liabilities (USD, thousands)

Long-term debt (USD, thousands)

Operating lease liability, net of current portion (USD, thousands)

Total liabilities (USD, thousands)

Common stock (USD, thousands)

Additional paid-in-capital (USD, thousands)

Accumulated deficit (USD, thousands)

Total stockholders’ equity (USD, thousands)

Total liabilities and stockholders’ equity (USD, thousands)

81c0b4c6a28e1270cbe48cc48d6d8bec5ec80a672c001cea30a5445fa8c0044d

Median seizure reduction at six months after implant for RNS System (percentage)

Median seizure reduction at thirty-six months after implant for RNS System (percentage)

Percentage of patients who experienced a period of seizure-freedom (percentage)

Percentage of patients who were seizure free (percentage)

Average daily stimulation for RNS System (minutes per day)

355c3b027c509b96905c8459d573634e11969118486830721f5438ba93b9e6f8

Revenue [USD, thousands]

Cost of Goods Sold [USD, thousands]

Gross Profit [USD, thousands]

Research and Development Expenses [USD, thousands]

Selling, General and Administrative Expenses [USD, thousands]

Total Operating Expenses [USD, thousands]

Loss from Operations [USD, thousands]

Interest Income [USD, thousands]

Interest Expense [USD, thousands]

Other Income (Expense), Net [USD, thousands]

Net Loss and Comprehensive Loss [USD, thousands]

0e0bdba40a116c620f4584b5fc11706d193570b88a2d7b1bae2bced161ad483c

Net loss [USD, thousands]

Stock-based compensation expense [USD, thousands]

Depreciation [USD, thousands]

Amortization of debt discount and issuance costs [USD, thousands]

Non-cash interest expense [USD, thousands]

PIK interest incurred but not paid on term loan [USD, thousands]

Amortization of right-of-use asset [USD, thousands]

(Gain) loss on short-term investments [USD, thousands]

Inventory write-downs [USD, thousands]

Other [USD, thousands]

Net cash used in operating activities [USD, thousands]

Acquisition of property and equipment [USD, thousands]

Proceeds from sale of short-term investments [USD, thousands]

Net cash provided by investing activities [USD, thousands]

Proceeds from issuance of common stock under employee plans [USD, thousands]

Taxes withheld and paid related to net share settlement of equity awards [USD, thousands]

Proceeds from At-the-Market offering, net of sales commission [USD, thousands]

Payment of deferred offering costs [USD, thousands]

Net cash provided by financing activities [USD, thousands]

Net (decrease) increase in cash and cash equivalents [USD, thousands]

Cash paid for interest [USD, thousands]

Net change in accrued liabilities from early exercise of options [USD, thousands]

Purchase of property and equipment included in accounts payable [USD, thousands]

Deferred offering costs offset against additional paid-in capital [USD, thousands]

Accounts receivable [USD, thousands]

Inventory [USD, thousands]

Prepaid expenses and other assets [USD, thousands]

Accounts payable [USD, thousands]

Accrued liabilities [USD, thousands]

Deferred revenue [USD, thousands]

Operating lease liabilities [USD, thousands]

Cash, cash equivalents and restricted cash, Beginning of year [USD, thousands]

Cash, cash equivalents and restricted cash, End of year [USD, thousands]

Cash and cash equivalents [USD, thousands]

Restricted cash [USD, thousands]

Total cash, cash equivalents and restricted cash [USD, thousands]

ea8563d42fddd2867b6d14882989b9d492021146ad3932cc2b65cef10bf7a4b0

United States

- Other regions

Total Revenue

0921e1f52532b91c32397715fbddf59ccd8050b848caf0e1af7d50b3ec069423

RNS System

- Replacement Procedures

DIXI Medical Products

Initial Implant Procedures

fe3d9437466c6af1625fe7e558662abce76e29420f56b96be0c02c119abac1b5

Neuropace Inc (NPCE)

Financials